Approaches to modeling, parameter estimation, and policy guidance during the endgame Guillaume Chabot-Couture Philip Eckhoff Mike Famulare Hao Hu Hil Lyons.

Slides:



Advertisements
Similar presentations
How can Modeling Help in Emerging Epidemics? John Grefenstette, PhD Public Health Dynamics Lab Health Policy & Management Pitt Public Health Dec 5, 2014.
Advertisements

Module 1 Introduction to the polio endgame rationale and IPV vaccine
Polio Eradication Dr Marvin Hsiao Division of Medical Virology NHLS/UCT/Groote Schuur Hospital.
Poliomyelitis Surveillance in Ireland 4 th April, 2014.
Hepatitis A and Hepatitis A Vaccine Epidemiology and Prevention of Vaccine- Preventable Diseases National Immunization Program Centers for Disease Control.
IPV IPV Rapidly produces high level of protective antibodies No risk of vaccine associated illness No interference from other enteroviruses. I.P.V. produces.
Measles outbreak investigation & Response Jordan DR MOHAMAD RATIB SUROUR NATIONAL EPI MANAGER INTER-COUNTRY MEETING ON MEASLES AND RUBELLA CONTROL AND.
Comparing Rubella Vaccination Strategies in China Linda Q. Gao North Central College Herbert Hethcote The University of Iowa May 18, 2004 DIMACS.
Poliomyelitis First described by Michael Underwood in 1789 First outbreak described in U.S. in ,000 paralytic cases reported in the U. S. in 1952.
CIDID Polio Modelers at The University of Michigan Epidemiology: Jim Koopman, Marisa Eisenberg, Joe Eisenberg, Christopher Henry, Xinyu Zhang Statistics:
WHO RAP Team: Perspective and Update WORKSHOP ON ANALYZING THE POLIO ERADICATION ENDGAME, Seattle, 1-2 July 2015.
Global Polio Eradication Initiative Surveillance, Operation and Monitoring Vaccine Procurement, Communication and Social Mobilization Advocacy, Funding.
Completing The Endgame Global Polio Eradication
How does mass immunisation affect disease incidence? Niels G Becker (with help from Peter Caley ) National Centre for Epidemiology and Population Health.
Infectious Disease Epidemiology Sharyn Orton, Ph.D. American Red Cross, Rockville, MD Suggested reading: Modern Infectious Disease Epidemiology (1994)
Neil Ferguson Dept. of Infectious Disease Epidemiology Faculty of Medicine Imperial College WG 7: Strategies to Contain Outbreaks and Prevent Spread ©
Polio eradication programme in India – Progress, Response and Issues for action Dr Ajay Khera Deputy Commissioner Ministry of Health & FW, Govt. of India.
The Evolving 'Polio Endgame' Strategy
Pan American Health Organization.. Protecting the Health of Health Care Workers: Experience from the Americas Marie-Claude Lavoie Decision Making for Using.
Conclusions & Recommendations 24 th IEAG March 2012.
Polio Update Pre Tender Meeting 11 th December 2008 UNICEF Supply Division.
Current strategy. Schedule The immunization schedule for infants recommended by the WHO Expanded Programme on Immunization AgeVaccines BirthBCG, OPV zero.
Completing Polio Eradication in Bihar 24 th January.
Polio End-game: What are the implications on polio vaccination policy? Dr Raju Shah.
Data in WHO HQ as of 09 October 2012 Highlights of New Wild Poliovirus Cases The boundaries and names shown and the designations used in the maps in this.
Polio and Polio Vaccine
1 Progress Towards Polio Eradication in EMR. 2 Status of global eradication Priority countries (except EMR) : Intensification : Certification,
VACCINES: PAST, PRESENT, AND FUTURE. Starry Night or Deadly Virus?
By Archana Bhasin. Poliomyelitis is a viral disease that can affect nerves and can lead to partial or full paralysis.
Progress of Polio Eradication in India, Current Risks & Actions taken on last IEAG report 24 th IEAG, New Delhi 15 March 2012 Dr. Ajay Khera Deputy Commissioner.
New vaccines mean new strategies: A theoretical exploration of the impact of HPV/HSV vaccines. Geoff Garnett Department of Infectious Disease Epidemiology,
Deliberations of the IEAG November IEAG Issues – Federal & State Gov'ts Why isn't epidemiology for type 1 and type 3 fully meeting IEAG projections.
Polio Eradication and End Game Strategy
Deliberations of the 23 rd IEAG July 2011.
Vaccine-Derived Poliovirus Infections in an Amish Population Minnesota, 2005 Harry F. Hull, M.D. State Epidemiologist Minnesota Department of Health.
Sustaining Polio Eradication IEAG March 2012 The experience of polio-free countries with importations of WPV: Implications for India.
TM OPV Stockpiling in the United States Trudy V. Murphy, M.D. National Immunization Program Centers for Disease Control and Prevention February 5, 2003.
Polio Endgame Strategy in India Considerations and Way Forward WHO-India, NPSP 15 March 2012.
1 Polio Strategic Plan India Expert Advisory Group July 2011 Impact & prospects at the half-way point.
Exploring issues of data quality in household surveys: Searching for explanations behind discrepant results for vaccination coverage across surveys of.
Epidemiology of Poliomyelitis Ashry Gad Mohamed MBchB, MPH, DrPH Prof. of Epidemiology Medical College, KSU.
Data in WHO HQ as of 17 Apr 2012 Highlights of New Wild Poliovirus Cases The boundaries and names shown and the designations used in the maps in this document.
Global Polio Eradication Initiative The 'Intensified Effort' 18 May 2008.
Situation overview and Meeting Objectives The Middle East Polio Outbreak Phase II Review.
Polio Research Activities in India Dr Sunil Bahl WHO-India, NPSP 15 March 2012.
Poliovirus Surveillance and Risks to Polio Eradication in India Dr. Hamid Jafari WHO-NPSP.
National Immunization Program (NIP)/Advisory Committee on Immunization Practices (ACIP) Report Stephen L. Cochi, MD, MPH Acting Director, National Immunization.
Poliovirus Surveillance status of quality, actions to improve sensitivity WHO-India 15 March 2012.
February 2015 An introduction to the switch from trivalent to bivalent oral polio vaccines 1.
The polio endgame and silent circulation: some related research.
Approaches to modeling, parameter estimation, and policy guidance during the endgame Dr Isobel BlakeDr Kath O’Reilly Research FellowMRC Research Fellow.
Module 1 Introduction to the polio endgame rationale and IPV vaccine
Polio and Polio Vaccine Epidemiology and Prevention of Vaccine- Preventable Diseases National Immunization Program Centers for Disease Control and Prevention.
Rubella Surveillance and Control in Low-Resource Settings: Limitations, Biases, and Potential for Strengthening Amy Winter, PhD Candidate, Princeton University.
Risk Modeling for District Prioritization in Pakistan Laina Mercer Steve Kroiss, Hil Lyons, Guillaume Chabot-Couture 20 April, 2016.
Integrated disease surveillance and care delivery: stories from polio (and weather) Mike Famulare.
Assessment of areas at increased risk for undetected poliovirus circulation in Ecuador Gustavo Dayan, MD Epidemiology Surveillance Division National Immunization.
Data quality for polio eradication: Accuracy & reliability
Jillian Gauld Institute for Disease Modeling April 20, 2017
Perspective and Update
The Role of Supplementary Immunization Activity Scheduling on Measles Incidence in Nigeria Kurt Frey April 20, 2017 IDM Disease Modeling Symposium Measles.
Vaccine-Derived Poliovirus Outbreak Minnesota, 2005
AMINU M,1 AHMAD A A1 and OGUNRINDE G O2
Influenza Vaccine Effectiveness Against Pediatric Deaths:
The Polio Eradication and Endgame Strategic Plan
المرحلة القادمة من القضاء على شلل الأطفال واللقاحات المستخدمة
Epidemiological Modeling to Guide Efficacy Study Design Evaluating Vaccines to Prevent Emerging Diseases An Vandebosch, PhD Joint Statistical meetings,
Community transmission of type 2 poliovirus after cessation of trivalent oral polio vaccine in Bangladesh: an open-label cluster-randomised trial and.
Maintaining Elimination in an Environment of Persistent Importation
Risk mapping Embedded tool for disease outbreak prevention
Presentation transcript:

Approaches to modeling, parameter estimation, and policy guidance during the endgame Guillaume Chabot-Couture Philip Eckhoff Mike Famulare Hao Hu Hil Lyons Kevin McCarthy Alex Upfill-Brown Bradley Wagner

IDM approach to polio research Focus on operational questions first Let the question choose the method Synthesize across disparate data sources and modeling tools – Statistical methods to extract maximal value from GPEI data – Dynamical models to develop understanding of mechanisms – Hybrid models that take advantage of good features of both This talk – Expanded Age Group campaigns – Modeling silent transmission near elimination – Understanding OPV transmission

Impact of Expanded Age Group Campaigns for Polio Eradication PLoS ONE 9(12): e Endemic setting (calibrated to Zaria, Nigeria) -Expanded age group (EAG) campaigns are unlikely to significantly improve prospects for polio elimination -Key concern is reaching inaccessible under- immunized populations -Insensitive to waning due to re-exposure from transmission Epidemic in polio-free setting -EAG campaigns can fill immunity gaps left by waning protected fraction mucosal waning rate (years) SIA coverage

Has Nigeria eliminated wild poliovirus? From the last case, model to extinction or the next case Dynamical transmission + statistical force of infection = efficient marginalization over uncertainty + near-real-time data assimilation to provide probabilistic forecasts When cases are rare, model the interval between cases March 31, 2015 Environmental Positive WPV1 probably eliminated from Nigeria WPV3 very likely eradicated cVDPV2 from established lineages likely persists Initialize prevalence based on the interval of the last 2 cases arXiv: Under review

Complementary to detailed spatial modeling Calibrated model used to estimate eradication probability given time since last polio paralysis case. Possibility of prior eradication and reimportation in Kano state in 2009/2010, when there was a 20-month silent period. Log 10 (Node Pop) DataSim DataSim McCarthy et al in prep Calibrated spatial model provides a system to study SIA campaign dynamics, cVDPV emergence

Spatial model data and calibration Statewide data informs disease model parameters – Incubation and infectious period, seasonal forcing peak and amplitude LGA-level targets inform network-level parameters – Migration rate, heterogeneity in coverage Incremental Mixture Importance Sampling used for parameter exploration/calibration

Phylogeography for polio is tough (and are phylodynamics too?) endemic poliopandemic influenza all branches well-resolved ancestor location The timescales of sampled genetic linkage and spatial mixing determine when sequence data is informative. PMID On 6 month timescales, dynamics are poorly resolved.

Recap so far -EAG campaigns are useful if polio is detected in previously polio-free settings -The effect of mucosal waning at naturally-acquired doses needs to be measured. -Hybrid statistical-dynamical models allow for efficient marginalization over uncertainty -This may be a promising approach for data assimilation and near-term forecasting -Detailed spatial models are useful for understanding determinants of polio persistance -May provide a platform for modeling outbreak response strategies Pieces of the OPV transmission puzzle -The biggest endgame challenge is detecting and preventing cVDPV emergence -Quantitative questions that affect our understanding of cVDPV risk -How transmissible is each OPV strain? -Can we mitigate uncertainties due to ignorance of population structure? -How does genetic reversion affect emergence?

Transmissibility of OPV inferred with SIR models R0 – by serology of unvaccinated children Detroit and Houston (Chen et al. 1996) 30% of unvaccinated months old are seropositive to type 2 Routine immunization rates known from dose histories Sero-prevalence among zero-dose children increases with R0 Location Age (months) Type 1Type 2Type 3 Detroit12 – (0.33 – 1.26)1.42 (0.84 – 2.20)0.42 (0.16 – 0.88) 24 – (0.19 – 1.34)1.97 (1.00 – 3.49)1.18 (0.52 – 2.22) Houston12 – (0.10 – 0.64)0.92 (0.50 – 1.51)0.59 (0.28 – 1.07) 24 – (0.15 – 1.48)1.77 (0.78 – 3.43)0.83 (0.26 – 1.86) Combined12 – (0.24 – 0.75)1.13 (0.76 – 1.59)0.48 (0.27 – 0.79) 24 – (0.23 – 1.08)1.92 (1.14 – 3.00)1.00 (0.51 – 1.72) Sabin 2 R0 likely greater than 1 R0 – by shedding at RI enrollment Mirpur, Dhaka (PROVDE study) 7% of children shedding OPV2 at 6 weeks of age POL3 coverage is 94% Shedding at enrollment increases with R0 R0 estimates range from 10 to 17 Model predicts ~30% of children get at least one naturally-acquired OPV2 infection during the first year of life

Social structure affects meaning of high R0 Vaccine recipient SiblingExtra-familial contact of sibling Low-income setting with low enterovirus background (1-2% of subjects) Primary recipients (n=352) Age 6-18 months 40% prior immunity (mostly IPV) Sibling contacts (n=657) 80% < 5 years old Extra-familial contacts of siblings (n=430) Similar demographics to siblings Inferences about transmissibility (only propagating infectivity uncertainty) High OPV efficacy (81-95%) Many monovalent, historical titers Intra-family transmissibility is high despite evidence for prior immunity R eff = 3.4 (2.4,4.3) Extra-familial transmissibility is lower R eff = 0.85 (0.5,1.3)

Challenge to predicting low probability events: network structure Network structure has profound effect on outbreak probability even when mean transmission dynamics are similar. Los Alamos Urban Network mean degree = 16.7 Total population = 100,000 Reproductive number = 1.8 “Power law” network mean degree = 2.0 Epidemic probability = 68% Final epidemic size = 60,000 Epidemic probability = 17% Final epidemic size = 20,000

Timescales of OPV reversion Worked with CDC and Nigeria polio Lab to study Sabin-like isolates from AFP surveillance in Nigeria Combined whole-genome sequencing with case history and polio infection model to infer substitution rates of early reversion Improved quantitative estimates of the circulation time required to reach the VDPV threshold Famulare et al under review poster available in meeting materials Potential for silent circulation of VDPV 1 and 3? VDPV case-to-infection ratios may not be wild-type

Matlab, Bangladesh OPV2 transmission study tOPV bOPV+1IPV bOPV+2IPV tOPV withdrawal April 2015 tOPV withdrawal Birth cohort and family stool survey 40% of birth cohort and 0-5 year old tOPV challenge Birth cohort and family stool surveys Stool sample at 6, 18 weeks age January 2016 Collaboration with UVA (Mami Tanuichi, Bill Petri) and icddr,b (Rashidul Haque, K Zaman) 1.Measure transmission of OPV2 after tOPV cessation 2.Measure transmission after OPV2 challenge 3.Measure individual protection to type 2 from different RI schedules

Environmental surveillance in a low infrastructure setting Testing feasibility and sensitivity of RT-qPCR for poliovirus surveillance in water Correlate ES with respect to stool surveillance -Seasonality of sensitivity -Demographics of sensitive sites -Identify principles of site selection for this type of setting? 1.Map from Google Earth along with GIS information from Matlab used to pick potential sites (201 total from 67 villages) 2.Visit villages as a team (lab technician, porter, and field worker) to survey the sites 3.Site selection based on number of users, surrounding latrines, and etc. 4.Monthly sampling

Opinions and questions for the group Quantifying endgame risks and OPV campaigns after cessation requires stacking up a lot of unknowns. We need to respect model misspecification, especially when attempting to predict absolute risks. -How do we mitigate model misspecification risk? -Relative risk ranking? -Efficient marginalization over uncertainty? -Deeper theoretical support for model structures? We need to clearly communicate data gaps and continue to help close them. How do we measure our way out of the risks? -What methodological improvements are required to improve surveillance and the utility of surveillance data?